The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure
- 2 May 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in Biomarkers
- Vol. 22 (8), 731-739
- https://doi.org/10.1080/1354750x.2017.1319421
Abstract
Objective: We tested the hypothesis that early measurement of galectin-3 at the emergency department (ED) during an episode of acute heart failure (AHF) allows predicting short- and long-term outcomes. Methods: We performed an exploratory study including 115 patients consecutively diagnosed with AHF in a single ED. Clinical and analytical variables were recorded. The primary endpoint was 30-day all-cause mortality, and secondary endpoints were 30-day composite outcome (death, rehospitalization or ED reconsultation, whichever first) and 1-year mortality. Results: Seven patients (6.1%) died within 30 days and 43 (37.4%) within 1 year. The 30-day composite endpoint was observed in 21.1% of patients. Galectin-3 was correlated with NT-proBNP and the glomerular filtration rate but not with age and s-cTnI. Measured at time of ED arrival, galectin-3 showed good discriminatory capacity for 30-day mortality (AUC ROC: 0.732; 95% CI 0.512–0.953; p = 0.041) but not for 1-year mortality (0.521; 0.408–0.633; p = 0.722). Patients with galectin-3 concentrations >42 μg/L had an OR = 7.67(95%CI = 1.57-37.53; p = 0.012) for 30-day mortality. Conversely, NT-proBNP only showed predictive capacity for 1-year mortality (0.642; 0.537–0.748; p = 0.014). Patients with NT-proBNP concentrations >5400 ng/L had an OR = 4.34 (95%CI = 1.93-9.77; p < 0.001) for 1-year mortality. These increased short- (galectin-3) and long-term (NT-proBNP) risks remained significant after adjustment for age or renal function. s-cTnI failed in both short- and long term death prediction. No biomarker predicted the short-term composite endpoint. Conclusion: These results suggest that galectin-3 could help to monitor the risk of short-term mortality in unselected patients with AHF attended in the ED.Keywords
Funding Information
- Instituto de Salud Carlos III
- FEDER (PI10/01918, PI11/01021, PI15/01019, PI15/00773)
- La Marató de TV3 (2015/2510)
- Catalonia Govern for Consolidated Groups of Investigation (GRC 2009/1385, 2014/0313)
This publication has 30 references indexed in Scilit:
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJournal of the American College of Cardiology, 2013
- Galectin 3 complements BNP in risk stratification in acute heart failureBiomarkers, 2012
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac CareEuropean Heart Journal, 2011
- Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatmentEuropean Heart Journal, 2010
- La monitorización de ST2 soluble proporciona una estratificación del riesgo adicional en pacientes ambulatorios con insuficiencia cardiaca descompensadaRevista Espanola de Cardiologia, 2010
- The regulation of inflammation by galectin‐3Immunological Reviews, 2009
- Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart FailureJournal of the American College of Cardiology, 2006
- Long-term clinical variation of NT-proBNP in stable chronic heart failure patientsEuropean Heart Journal, 2006
- Survival after the onset of congestive heart failure in Framingham Heart Study subjects.Circulation, 1993